142 related articles for article (PubMed ID: 16075280)
1. Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells.
Lee J; Zhou HJ; Wu XH
Cancer Chemother Pharmacol; 2006 Jan; 57(2):213-20. PubMed ID: 16075280
[TBL] [Abstract][Full Text] [Related]
2. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells.
Zhou HJ; Wang WQ; Wu GD; Lee J; Li A
Vascul Pharmacol; 2007; 47(2-3):131-8. PubMed ID: 17581794
[TBL] [Abstract][Full Text] [Related]
3. [Dihydroartemisinin inhibits the expression of vascular endothelial growth factor in K562 cells].
Li J; Zhou HJ
Yao Xue Xue Bao; 2005 Nov; 40(11):1041-5. PubMed ID: 16499092
[TBL] [Abstract][Full Text] [Related]
4. Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression.
Zhou HJ; Wang Z; Li A
Anticancer Drugs; 2008 Mar; 19(3):247-55. PubMed ID: 18510170
[TBL] [Abstract][Full Text] [Related]
5. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Lee J; Shen P; Zhang G; Wu X; Zhang X
Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
[TBL] [Abstract][Full Text] [Related]
6. [Effect of dihydroartemisinin on the expression of BCR/ABL fusion gene in leukemia K562 cells].
Gao JL; Ding XP; Li QJ; Xia ZL; Xia QJ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Feb; 29(1):19-22. PubMed ID: 22311485
[TBL] [Abstract][Full Text] [Related]
7. Antimalarial dihydroartemisinin also inhibits angiogenesis.
Chen HH; Zhou HJ; Wang WQ; Wu GD
Cancer Chemother Pharmacol; 2004 May; 53(5):423-32. PubMed ID: 15132130
[TBL] [Abstract][Full Text] [Related]
8. Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion.
Wu XH; Zhou HJ; Lee J
Anticancer Drugs; 2006 Aug; 17(7):839-48. PubMed ID: 16926633
[TBL] [Abstract][Full Text] [Related]
9. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
10. [Effects of Scutellaria Barbata on VEGF Expression in K562 Cells].
Shi R; Guo SQ; Liu S; Li ZS; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1339-1342. PubMed ID: 27784353
[TBL] [Abstract][Full Text] [Related]
11. [Dihydroartemisinin down-regulates the expression of transferrin receptor in myeloid leukemia cells].
Wang Z; Zhou HJ
Yao Xue Xue Bao; 2008 Jun; 43(6):576-83. PubMed ID: 18822958
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
Zhu XS; Lin ZY; Du J; Cao GX; Liu G
Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
Chen HH; Zhou HJ; Wu GD; Lou XE
Pharmacology; 2004 May; 71(1):1-9. PubMed ID: 15051917
[TBL] [Abstract][Full Text] [Related]
14. [Anti-angiogenesis of interferon-alpha2b in chronic myeloid leukemia in vitro].
Zhang LM; Yu YZ; Huang ZP; Zhang WS; Dong L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):291-5. PubMed ID: 20416154
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro.
Xiao Z; Wang Y; Lu L; Li Z; Peng Z; Han Z; Hao Y
Leuk Res; 2006 Jan; 30(1):54-9. PubMed ID: 15982734
[TBL] [Abstract][Full Text] [Related]
16. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y
Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
18. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic effect of As2S2 on K562 cells and its mechanism.
Li JE; Wu WL; Wang ZY; Sun GL
Acta Pharmacol Sin; 2002 Nov; 23(11):991-6. PubMed ID: 12421474
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
